Who are paclitaxel plus carboplatin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): docetaxel and carboplatin, docetaxel - cisplatin - 5-fluorouracil.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/paclitaxel-plus-carboplatin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

paclitaxel plus carboplatin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

paclitaxel plus carboplatin (paclitaxel plus carboplatin) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Taxane and platinum-based chemotherapy. Area: Oncology.

phase 3 Taxane and platinum-based chemotherapy Oncology Small molecule Live · refreshed every 30 min

Target snapshot

paclitaxel plus carboplatin (paclitaxel plus carboplatin) — Immatics US, Inc.. Paclitaxel works by inhibiting cell division, while carboplatin interferes with DNA repair, both leading to cell death in rapidly dividing cancer cells.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
paclitaxel plus carboplatin TARGET	paclitaxel plus carboplatin	Immatics US, Inc.	phase 3	Taxane and platinum-based chemotherapy
docetaxel and carboplatin	docetaxel and carboplatin	Sanofi	phase 3	Taxane and platinum-based chemotherapy
docetaxel - cisplatin - 5-fluorouracil	docetaxel - cisplatin - 5-fluorouracil	Gruppo Oncologico del Nord-Ovest	phase 3	Taxane and platinum-based chemotherapy	Microtubules and DNA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Taxane and platinum-based chemotherapy class)

Gruppo Oncologico del Nord-Ovest · 1 drug in this class
Immatics US, Inc. · 1 drug in this class
Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). paclitaxel plus carboplatin — Competitive Intelligence Brief. https://druglandscape.com/ci/paclitaxel-plus-carboplatin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab